Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC Enxin WangDongdong XiaGuohong Han PRECLINICAL STUDIES 18 July 2018 Pages: 401 - 414
Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro Jürgen WeinreichFlorian StrullerTimm C. Schott PRECLINICAL STUDIES 18 July 2018 Pages: 415 - 423
Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation Su Myat PhyuTim A. D. Smith PRECLINICAL STUDIES Open access 28 July 2018 Pages: 424 - 430
Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model Martin PerreaultRené MaltaisDonald Poirier PRECLINICAL STUDIES 30 July 2018 Pages: 431 - 440
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer Alexandra CanoniciLaura IversJohn Crown PRECLINICAL STUDIES 30 July 2018 Pages: 441 - 451
A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2 Hui HuangJunxing NiuQiang Yu PRECLINICAL STUDIES 03 August 2018 Pages: 452 - 460
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors Antonio JimenoKathleen N. MooreDavid C. Smith PHASE I STUDIES 19 September 2018 Pages: 461 - 472
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer Amit MahipalSri Harsha TellaRichard Kim PHASE I STUDIES 09 October 2018 Pages: 473 - 481
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer G. Weldon GilcreaseDavid D. StenehjemSunil Sharma PHASE I STUDIES 10 October 2018 Pages: 482 - 489
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials Audrey E. KamGopichand PendurtiSanjay Goel PHASE I STUDIES 12 October 2018 Pages: 490 - 497
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens J. R. GoffinG. NicholasP. A. Bradbury PHASE I STUDIES 13 October 2018 Pages: 498 - 506
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors Toshihiko DoiKiyotaka YohJunji Furuse PHASE I STUDIES Open access 04 December 2018 Pages: 507 - 518
Increasing complexity in oncology phase I clinical trials Laeeq MalikDavid Lu SHORT REPORT 16 November 2018 Pages: 519 - 523
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer Giandomenico RovielloRoberto PetrioliMichele Aieta PHASE II STUDIES 28 January 2019 Pages: 524 - 530
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma Norimichi AkiyamaMasato KarayamaTakafumi Suda PHASE II STUDIES 21 February 2019 Pages: 531 - 537
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial Kenichi InoueJun Ninomiyafor the SBCCSG-36 investigators PHASE II STUDIES Open access 08 March 2019 Pages: 538 - 547
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma M. Christina CoxSabrina PellicciaGerardo Musuraca PHASE II STUDIES 26 April 2019 Pages: 548 - 558
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer Vadim S. KoshkinMaria C. MirJorge A. Garcia PHASE II STUDIES 30 April 2019 Pages: 559 - 566
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma Changhoon YooJoong-Won ParkHo Yeong Lim SHORT REPORT 07 December 2018 Pages: 567 - 572
Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study Hanae IdaYoshitaka HonmaNarikazu Boku SHORT REPORT 28 September 2018 Pages: 573 - 578
Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review Hyeon CheunMiso KimBhumsuk Keam SHORT REPORT 08 October 2018 Pages: 579 - 583
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores Inhwan HwangJihoon KangBaek-Yeol Ryoo SHORT REPORT 16 October 2018 Pages: 584 - 590
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor Tetsuhide ItoTakuji OkusakaMasayuki Imamura Correction 23 March 2019 Pages: 591 - 591
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial Kenichi InoueJun Ninomiyafor the SBCCSG-36 investigators Correction 25 April 2019 Pages: 592 - 593
